A recent study reveals that patients who stop using new weight-loss injections like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who stop traditional lifestyle regimens.
Research printed in a prominent health publication demonstrates that while overweight individuals can lose about a fifth of their total mass while using the jabs, the mass returns at an average rate of nearly a kilo each month upon discontinuation.
"Individuals purchasing these medications must be aware of the risk of fast weight regain when the treatment is stopped," cautioned researcher Dr. Susan Jebb.
This pace of regain means a return to original mass in about one and a half years.
Analyzing Therapies
The research, which examined 37 of trials involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with older methods.
The team point out that individuals who shed pounds through lifestyle changes alone generally have a less rapid creep back—around 0.1 kg a month—once they finish.
Explaining the Fast Regain
Doctors propose the way of the drugs is key to understanding the heightened rebound.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and could reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication results in appetite is unsuppressed, making excessive eating a significant risk."
A Chronic Condition?
The NHS advise the injections for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Many experts say that, considering the likelihood of weight regain, the treatment is often long-term.
This opinion is reinforced by drug manufacturers, who say that the results "highlight the long-term nature of obesity," similar to managing conditions like diabetes.
Patient Accounts
People who have come off the medication explain a powerful return of appetite.
"I experienced something flipping and you become starving," described an individual.
This challenge is worsened if patients have not developed lasting dietary or behavioural modifications during therapy.
Significant Adoption
Survey data indicate that millions of people in the UK have tried these injections in the last 12 months, with demand being substantial.
- Use is greater among females compared to males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while these medications are powerful agents for shedding pounds, they are not a standalone cure and lasting health benefits likely depends on integrated behavioural changes.
